Dr. Erlinda Maria Gordon, MD

Expert Publications

• Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic t
• Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.
• First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
• Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype.
• Gene therapy in a murine model for clinical application to multiple sclerosis.
• Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors.
• Nanotechnology blooms, at last (Review).
• Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.
• Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.
• The 'timely' development of Rexin-G: first targeted injectable gene vector (review).
• Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
• Rexin-G, a targeted genetic medicine for cancer.
• Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent.
• Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.

Clinical Trials

• Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma
• Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma

Media Releases

Get to know Pediatric Hematologist-Oncologist Dr. Erlinda Maria Gordon, who serves patients in Santa Monica, California.

Dr. Gordon is an experienced pediatric hematologist-oncologist, cancer drug developer, biopharmaceutical founder and executive with a proven track record in translational biomedical research, patient care and cancer drug development. Currently, she serves as the Director of Biological and Immunological Therapies and the Chairman of the NIH-approved Institutional Biosafety Committee at the Sarcoma Oncology Center in Santa Monica, California.

The mission of the Sarcoma Oncology Center is to provide the best possible care for all their cancer patients. They promise to support their patients and offer the best possible care regardless of the gravity of their illness. Meeting their patients’ medical and personal needs is their highest priority. They give clear and comprehensive information to help them make informed decisions and participate in their own medical care. They believe that compassion and mutual respect are essential for success in meeting all the dimensions of cancer care.

A native of the Philippines, Dr. Gordon received her medical degree from the University of Santo Tomas Medical College of Medicine and Surgery in 1971. Upon relocating to the United States, she completed her residency in anatomic & clinical pathology with the MetroHealth System in 1974, and her residency in pediatrics at the same educational venue in 1976. Finally, she completed her fellowship in pediatric hematology/oncology at the Case Western Reserve University in 1978.

A Diplomate of the American Board of Pediatric Hematology/Oncology, she was a Tenured Associate Professor for 24 years and is a Professor Emeritus at the USC Keck School of Medicine in Los Angeles, California. There, she licensed the First Academic Vector Production Unit at the Norris Comprehensive Cancer Center, served as its first Medical Director for eight years, and was the Gene Therapy Sponsor for clinical protocols using Targeted Genetic Medicines for Cancer.

Furthermore, Dr. Gordon is the co-founder of two biotechnology companies and is a pioneer in the development of targeted gene therapy products. In her position as FDA liaison for these companies, she gained FDA orphan drug approval and fast track designation for pancreatic cancer, soft tissue sarcoma and osteosarcoma and accelerated approval for Rexin-G, the world’s first targeted genetic medicine for cancer.

Throughout her illustrious career, she has been the co-inventor of more than 150 patents in biomedical research, and patented the first targeted gene delivery system for cancer in the USA, Europe and the Philippines. She has authored more than 100 original peer-reviewed articles and served as Editor-in-Chief of the International Journal of Pediatric Hematology-Oncology, Director of the Red Cell Defects Program and the NIH-funded Comprehensive Hemophilia Center at Children’s Hospital of Los Angeles and the NIH-funded Children’s Oncology Group.

Pediatric oncology is a medical specialty focused on the care of children with cancer. A pediatric hematologist/oncologist is a physician who has special training and experience to diagnose and treat blood disorders and cancers in children, teens, and young adults.

As a testament to her success, Dr. Gordon has been the recipient of the Los Angeles Award for Excellence in Biotechnology Research, the National Institutes of Health Research Career Development Award and NIH/FDA funded grant awards. She was also a nominee for the prestigious Thomas Award for Excellence in Research in 2016.

Recommended Articles

• Recent Documentary Showcases an Autism Relationship

  Dina Buno is the star and subject of a documentary film directed and produced by Antonio Santini and Dan Sickles, titled Dina, which premiered at the 2017 Sundance Film Festival.She is also on the autism spectrum, as is her companion, Scott Levin. The documentary follows a year in their lives as...

• Oxygen Supply Management for COPD Patients

  When an individual has COPD, air is being blocked because of the tightening of the airways due to inflammation (bronchitis), and it is also possible for the patient to experience alveolar over-inflation (emphysema). The latter condition creates a problem to the exchange of oxygen and carbon dioxide,...

• Alcohol and Other Factors that Affect Recovery from Mononucleosis

  What is Mononucleosis?Mononucleosis (also known as mono) is a disease that usually arises from the Epstein-Barr virus and is spread through a person's saliva and other bodily fluids. The length and severity of this illness both differ from one person to another. Most people suffering from from mono...

• What Are the Benefits of Pilates?

  This method, introduced by Joseph Pilates, is in high demand and everybody seems to be practicing it in one form or the other. And many seem to be happy with the improvement they have in flexibility, abdominal strength and range of motion after starting with Pilates. What is Pilates? It is a series...

• How is Tennis Elbow Diagnosed?

  How is Tennis Elbow Diagnosed?Tennis elbow, also called lateral epicondylitis - is a very painful condition of the elbow resulting from elbow overuse. It is no surprise that you can get this problem from playing tennis or any other racquet sports. However, other activities can put you at risk for...

• What Are Roundworms?

  What are roundworms?Roundworms are a type of parasitic worms that infect the human intestine. Roundworms may vary and size and have a characteristic long, round body. These parasitic worms can cause a number of health problems in humans. They can enter the human body through the mouth and direct...